Quantitative Concept – Page 7

FDA Acting CDER Head Jacqueline Corrigan-Curay to Retire Amid Leadership Turnover

3 months ago talkbio0Tagged agency departures, CDER, Drug Regulations, Jacqueline Corrigan-Curay, Leadership, Personnel Turnover, Retirement, United States Food and Drug Administration

FDA; Jacqueline Corrigan-Curay; CDER; retirement; leadership turnover; drug regulation; agency departures

Amgen Adjusts Phase 3 Dosing for MariTide After Midstage Side Effects Concerns

3 months ago talkbio0Tagged Adverse event, amgen, Clinical Trials, Dosage, Escalation, gastric inhibitory polypeptide receptor, GLP-1 receptor, MariTide, Obesity, Phase 3, Vomiting

Amgen; MariTide; Phase 3; obesity treatment; dose escalation; vomiting; adverse events; clinical trial; GLP-1 receptor; GIP receptor

Exelixis’ Zanzalintinib Achieves Key Survival Goal in Pivotal Colorectal Cancer Study

3 months ago talkbio0Tagged atezolizumab, checkpoint inhibitor, Clinical Trials, Colorectal Carcinoma, Exelixis, Overall Survival, STELLAR-303, Stivarga, zanzalintinib

Exelixis; zanzalintinib; colorectal cancer; pivotal trial; overall survival; atezolizumab; checkpoint inhibitor; Stivarga; STELLAR-303; clinical trial

Scholar Rock’s SMA drug helps Zepbound patients retain muscle in phase 2 trial

3 months ago talkbio0Tagged apitegromab, GDF8 protein, human, Inhibitor, Lean Mass, muscle preservation, Obesity, Phase 2 trial, Scholar Rock, Spinal Muscular Atrophy, Weight Loss, Zepbound

Scholar Rock; apitegromab; SMA drug; Zepbound; tirzepatide; muscle preservation; obesity; weight loss; phase 2 trial; lean mass; myostatin inhibitor

Trump Administration Considers Limits on Direct-to-Consumer Drug Advertising

3 months ago talkbio0Tagged Ditiocarb, drug price, executive order, Health Policy, Pharma, pharmaceutical regulation, Transplant Registry Unified Management Program

Trump administration; DTC drug advertising; pharmaceutical regulation; drug pricing; executive order; health policy; pharma marketing

Beyond Theory: Real-World AI Wins in Life Science R&D – Faster & Smarter

3 months ago talkbio0Tagged Aortic Valve Insufficiency, Biological Science Disciplines, Clinical Trials, Drug Discovery, Efficiency, Financial cost, Infrequent, R&D, trends qualifier

AI in life sciences; R&D efficiency; drug discovery; clinical trials; pharma innovation; 2025 AI trends; cost reduction; rare diseases

Senate Drops Orphan Cures Act from Trump’s Tax Bill, Dealing Setback to Biopharma

3 months ago talkbio0Tagged Beak, Big Beautiful Bill, Biopharma, Drugs, Orphan, healthcare legislation, Infrequent, Ira (eukaryote), Mediation, Orphan Cures Act, Prices, reconciliation, Senate, Transplant Registry Unified Management Program

Orphan Cures Act; orphan drugs; Trump tax bill; biopharma; Senate; IRA price negotiations; rare diseases; Big Beautiful Bill; healthcare legislation; reconciliation bill